Citations

Clear

1819 citation(s) found for "Israel, E".

Probing the Virtual Proteome to Identify Novel Disease Biomarkers
Smith, J. G. , Melander, Olle , Ngo, Debby , Shaffer, Christian M., Ferguson, Jane F. , Herzig, Matthew , McCarty, Catherine A. , Jarvik, Gail P. , Gordon, Allan , Palmer, Melody R. , Crosslin, David R. , Larson, Eric B. , Pacheco, Jennifer A. , Peissig, Peggy , Brilliant, Murray H. , Kitchner, Terrie, Linneman, James G., Namjou, Bahram , Ritchie, Marylyn D. , Borthwick, Kenneth M., Kiryluk, Krzysztof , Mentch, Frank , Sleiman, Patrick , Karlson, Elizabeth W. , Zhu, Yineng, Denny, Joshua C. , Roden, Dan M. , Gerszten, Robert E. , Wang, Thomas J. , Denny, Joshua C , Jarvik, Gail P , Gordon, Adam S , Pacheco, Jennifer A , Kiryluk, Krzysztof , Ferguson, Jane F , Mosley, Jonathan D , Benson, Mark D. , Chute, Christopher G. , Carrell, David , Kullo, Iftikhar J. , Williams, Marc S , Verma, Shefali S. , Vasan, Ramachandran S. , Yang, Qiong , Roden, Dan M. , Smith, J Gustav

Mayo Clinic

Circulation | January 7, 2019 | Volume: 138 | Issue: 22 | Pages: 2469-2481

10.1161/circulationaha.118.036063 | PMID 30571344 Get It

Background: Proteomic approaches allow measurement of thousands of proteins in a single specimen, which can accelerate biomarker discovery. However, applying these technologies to massive biobanks is not currently feasible because of the practical barriers and costs of implementing such assays at scale. To overcome these challenges, we used a “virtual proteomic” approach, linking genetically predicted protein levels to clinical diagnoses in >40 000 individuals. Methods: We used genome-wide association data from the Framingham Heart Study (n=759) to construct genetic predictors for 1129 plasma protein levels. We validated the genetic predictors for 268 proteins and used them to compute predicted protein levels in 41 288 genotyped individuals in the Electronic Medical Records and Genomics (eMERGE) cohort. We tested associations for each predicted protein with 1128 clinical phenotypes. Lead associations were validated with directly measured protein levels and either low-density lipoprotein cholesterol or subclinical atherosclerosis in the MDCS (Malmö Diet and Cancer Study; n=651). Results: In the virtual proteomic analysis in eMERGE, 55 proteins were associated with 89 distinct diagnoses at a false discovery rate q<0.1. Among these, 13 associations involved lipid (n=7) or atherosclerosis (n=6) phenotypes. We tested each association for validation in MDCS using directly measured protein levels. At Bonferroni-adjusted significance thresholds, levels of apolipoprotein E isoforms were associated with hyperlipidemia, and circulating C-type lectin domain family 1 member B and platelet-derived growth factor receptor-β predicted subclinical atherosclerosis. Odds ratios for carotid atherosclerosis were 1.31 (95% CI, 1.08–1.58; P =0.006) per 1-SD increment in C-type lectin domain family 1 member B and 0.79 (0.66–0.94; P =0.008) per 1-SD increment in platelet-derived growth factor receptor-β. Conclusions: We demonstrate a biomarker discovery paradigm to identify candidate biomarkers of cardiovascular and other diseases.
BRCA1/BRCA2 (BRCA) testing in young women with breast cancer: Patterns, motivations, and implications for treatment decisions.
Rosenberg, Shoshana M. , Ruddy, Kathryn J. , Gelber, Shari , Schapira, Lidia , Come, Steven E. , Larsen, Bryce G., Tamimi, Rulla M. , Borges, Virginia F. , Garber, Judy E. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 6548-6548

10.1200/jco.2014.32.15_suppl.6548 Get It

A phase 2 study of 99m Tc-trofolastat chloride (MIP-1404) SPECT/CT to identify and localize prostate cancer (PCa) in high-risk patients (pts) undergoing radical prostatectomy (RP) and extended pelvic lymph node (ePLN) dissection compared to hist
Slawin, Kevin M., Tenke, Péter , Joniau, Steven , Ellis, William J., Buzogány, István, Мишугин, С. В. , Stolz, Josef, Матвеев, В. Б. , Karnes, R. Jeffrey , Jarrard, David Frasier, Yuh, Bertram, Trabulsi, Edouard J. , Stambler, Nancy , Armor, Thomas, Israel, Robert J. , Joniau, Steven , Alekseev, B. Yа. , Klein, Eric A. , Študent, Vladimír , Scherr, Douglas S. , Babich, John W.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e16003-e16003

10.1200/jco.2014.32.15_suppl.e16003 Get It

Variability in calcium/magnesium (CaMg) use for prevention of oxaliplatin-associated neuropathy.
Ruddy, Kathryn J. , Pachman, Dierdre, Haas, Lindsey R., Grothey, Axel, Shah, Nilay D. , Beutler, Andreas S. , Grendahl, Darryl C., Loprinzi, Charles L. , Hubbard, Jacqueline A. , Hubbard, Joleen M.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e14644-e14644

10.1200/jco.2014.32.15_suppl.e14644 Get It

HALO 110-101: A phase Ib, randomized, open-label study of PEGPH20 (pegvorhyaluronidase alfa) in combination with cisplatin (CIS) + gemcitabine (GEM) (PEGCISGEM) or atezolizumab and CIS + GEM (PEGCISGEMATEZO) in hyaluronan-high subjects with locally advance
Shroff, Rachna T. , Hecht, J. Randolph , Bullock, Andrea J. , Ritch, Paul S., Chondros, Dimitrios, Muhsin, Mann, Oh, Do‐Youn , Borad, Mitesh J. , Abou‐Alfa, Ghassan K.

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: TPS543-TPS543

10.1200/jco.2018.36.4_suppl.tps543 Get It

TPS543 Background: Cholangiocarcinoma (CCA) is treated with CIS and GEM (CISGEM), but prognosis is poor. Hyaluronan (HA) accumulation in solid tumors may impede drug and immune cell access. PEGPH20 targets tumors that accumulate HA (HA-high). This study (NCT03267940) plans to enroll 70 subjects to evaluate the safety and activity of PEGPH20 + programmed cell death-ligand 1 (PD-L1) agent atezolizumab, (PEGCISGEMATEZO), & PEGPH20 + CISGEM (PEGCISGEM) in HA-high subjects with CCA and gallbladder cancer. Study will comprise initial run-in and expansion portions. Primary endpoints include incidence of AEs and other laboratory/safety parameters and ORR (RECIST v1.1). Secondary endpoints include PK parameters; DOR, DCR, PFS, and ORR (RECIST v1.1 and immune-modified RECIST); and OS and OS by PD-L1 expression. Methods: ~6 HA-high subjects will be enrolled in PEGCISGEM arm run-in portion and undergo at ≥1 cycle; subsequently, 6 HA-high subjects will enter the PEGCISGEMATEZO arm. Treatment period will be 21-day cycles. In the expansion portion, ~50 HA-high subjects will be enrolled and randomized in a 2:2:1 ratio into PEGCISGEMATEZO, PEGCISGEM, and CISGEM arms. PEGPH20 is planned to be administered at 3.0 μg/kg on Days 1, 8 and 15 of all cycles in both portions. ATEZO will be administered at 1200 mg 1–3 hours after PEGPH20 on Day 1 of each 21-day cycle in the PEGCISGEMATEZO arm in both portions. In the PEGCISGEM & PEGCISGEMATEZO arms, dosing schedule for CISGEM is the same during both portions, with administration of 25 mg/m2 CIS and 1000 mg/m2 GEM on Days 2 and 9 of each cycle. In CISGEM control arm (expansion only), dosing schedule will be on Days 1 and 8 of each cycle. Treatment will continue until death, withdrawal of consent, disease progression, or unacceptable toxicity. Tumor response will be evaluated using RECIST v1.1. AEs will be graded per NCI CTCAE v4.03. Tumor samples will be tested retrospectively for PD-L1 expression. Safety data will be periodically monitored by an independent data monitoring committee. Clinical trial information: NCT03267940.
Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist.
Epelbaum, Ron, Semenisty, Valeriya, Geva, Ravit, Golan, Talia , Borazanci, Erkut , Wolpin, Brian M. , Ramirez, Robert A. , Becerra, Carlos, Shaw, Stephen M., Oberkovitz, Galia, Sorani, Ella, Lustig, Tzipora M, Haras, Abi Vainstein, Peled, Amnon , Hoff, Daniel D. Von , Borazanci, Erkut , Hidalgo, Manuel , Stemmer, Salomon M. , Borad, Mitesh J. , Park, Joon Oh , Pedersen, Katrina S. , Ramirez, Robert A

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: 276-276

10.1200/jco.2018.36.4_suppl.276 Get It

276 Background: BL-8040 is a novel CXCR4 antagonist being developed for multiple oncology indications. Preclinical studies demonstrated that BL-8040 increases the number of immune cells in peripheral blood and promotes CD8+ T cell infiltration into orthotropic pancreatic mouse tumors, reducing tumor load. BL-8040 is being evaluated in a Phase 2a, multicenter, open label trial in patients with metastatic pancreatic cancer (the COMBAT study). Patients are undergoing a 5-day period of monotherapy in which they receive daily doses of BL-8040, followed by 21-day cycles in which patients receive one dose of pembrolizumab and 3 doses/week of BL-8040 until disease progression or discontinuation. To date, 32 patients have been enrolled. Methods: On Day 1 and Day 5, blood samples were taken at pre- and post-dosing, to evaluate peripheral immune cell subset frequency by flow cytometry. In addition, core biopsies were taken from liver metastases, where possible, to assess immune cell infiltration into tumors and the tumor microenvironment (TME). Results: Here we present interim PD biomarker data from the BL-8040 monotherapy portion of the trial. Flow cytometry shows that BL-8040 monotherapy caused an approximately two-fold reduction in frequency of peripheral T regulatory cells, but had no effect on the frequency of T cells, NKT cells or cell populations that contain B cells (CD3- CD56-). Additionally, BL-8040 remained bound to CXCR4 on peripheral immune cells throughout the period of monotherapy. Analysis of available biopsies (N = 7) shows an up to 15-fold increase in the CD3+ population, and up to two-fold increase of CD8+ cells, in the tumor periphery and TME of 43% (3/7) of the patients after five days of BL-8040 monotherapy compared to baseline. Conclusions: In summary, the PD biomarker results in humans support the proposed mechanism of action for BL-8040 that was based on preclinical mouse models. Analysis of tumor biopsies is ongoing, with an emphasis on investigating the effects of BL-8040 on tumor-resident immune cells and the TME. Clinical trial information: NCT02826486.
American Head and Neck Society Endocrine Section clinical consensus statement: North American quality statements and evidence‐based multidisciplinary workflow algorithms for the evaluation and management of thyroid nodules
Meltzer, Charles , Irish, Jonathan C. , Busaidy, Naifa L. , Dwojak, Sunshine , Haugen, Bryan R. , Harrell, R. Mack, Haymart, Megan R. , McIver, Bryan, Monteiro, Eric, Odell, Michael , Scharpf, Joseph , Shaha, Ashok R. , Shin, Jennifer J. , Thompson, Geoffrey B. , Tuttle, R. Michael , Urken, Mark L. , Wiseman, Sam M. , Meltzer, Charles J , Angelos, Peter , Davies, Louise , Ferris, Robert L. , Mechanick, Jeffrey I. , Morris, John C., Morris, Luc G T , Shonka, David C. , Wong, Richard J. , Randolph, Gregory William

Mayo Clinic

Head & Neck | December 18, 2018 | Volume: 41 | Issue: 4 | Pages: 843-856

10.1002/hed.25526 | PMID 30561068 Get It

AbstractBackgroundCare for patients with thyroid nodules is complex and multidisciplinary, and research demonstrates variation in care. The objective was to develop clinical guidelines and quality metrics to reduce unwarranted variation and improve quality.MethodsMultidisciplinary expert consensus and modified Delphi approach. Source documents were workflow algorithms from Kaiser Permanente Northern California and Cancer Care of Ontario based on the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer.ResultsA consensus‐based, unified preoperative, perioperative, and postoperative workflow was developed for North American use. Twenty‐one panelists achieved consensus on 16 statements about workflow‐embedded process and outcomes metrics addressing safety, access, appropriateness, efficiency, effectiveness, and patient centeredness of care.ConclusionA panel of Canadian and United States experts achieved consensus on workflows and quality metric statements to help reduce unwarranted variation in care, improving overall quality of care for patients diagnosed with thyroid nodules.
History‐indicated cervical cerclage in management of twin pregnancy
Rottenstreich, Amihai , Levin, Gabriel , Kleinstern, Geffen , Zigron, Roy, Rottenstreich, Misgav , Elchalal, Uriel , Yagel, Simcha , Levin, G , Yagel, S , Rottenstreich, M

Mayo Clinic

Ultrasound in Obstetrics & Gynecology | December 14, 2018 | Volume: 54 | Issue: 4 | Pages: 517-523

10.1002/uog.20192 | PMID 30549119 Get It

ABSTRACTObjectiveCervical cerclage, when performed in twin gestation, has been reported to be associated with poor outcome. However, the role of first‐trimester history‐indicated cerclage among women with a twin pregnancy and a history of preterm birth has not been evaluated. The aim of this study was to assess pregnancy outcomes among women with a twin pregnancy who underwent first‐trimester history‐indicated cervical cerclage compared with outcomes in those managed expectantly.MethodsThis was a retrospective matched case–control study. The study group comprised all women with a twin pregnancy who had undergone first‐trimester history‐indicated cerclage during the period 2006 to 2017 at Hadassah‐Hebrew University Medical Center. A control group of women with a twin pregnancy who were managed expectantly was established by matching age, history of spontaneous preterm birth (20–36 weeks' gestation) and year of delivery. Pregnancy and delivery characteristics and neonatal outcomes were compared between the two groups.ResultsData from 82 women with a twin gestation were analyzed, of whom 41 underwent first‐trimester history‐indicated cerclage and 41 were matched controls who were managed expectantly. Gestational age at delivery was higher in the cerclage group than in those managed expectantly (median 35 vs 30 weeks; P < 0.0001). Rates of spontaneous preterm birth before 24 weeks (2.4% vs 19.5%; odds ratio (OR), 0.10 (95% CI, 0.01–0.87); P = 0.03), before 28 weeks (12.2% vs 34.1%; OR, 0.27 (95% CI, 0.09–0.84); P = 0.03), before 32 weeks (22.0% vs 56.1%; OR, 0.22 (95% CI, 0.08–0.58); P = 0.003) and before 34 weeks (34.1% vs 82.9%; OR, 0.11 (95% CI, 0.04–0.30); P < 0.0001) were significantly lower in the cerclage group than in the control group. Median birth weight was higher in the cerclage group (2072 g vs 1750 g; P = 0.003), with lower rates of low birth weight (< 2500 g) (65.0% vs 89.4%; P = 0.001) and very low birth weight (< 1500 g) (21.3% vs 37.9%; P = 0.03) than in the group managed expectantly. Rates were also lower in the cerclage group for stillbirth, admission to the neonatal intensive care unit, respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis, sepsis, neonatal mortality and composite adverse neonatal outcome.ConclusionsHistory‐indicated cerclage performed in the first trimester, as compared with expectant management, in women with a twin pregnancy had an overall positive effect on pregnancy and neonatal outcomes. These findings suggest the need for adequate randomized trials on cerclage placement in this subset of women. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.
Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines
Théry, Clotilde , Witwer, Kenneth W. , Aïkawa, Elena , Alcaraz, María José , Anderson, Johnathon D. , Andriantsitohaina, Ramaroson , Antoniou, Anna , Arab, Tanina , Archer, Fabienne , Atkin‐Smith, Georgia K. , Ayre, D. Craig , Bach, Jean‐Marie , Bachurski, Daniel , Baharvand, Hossein , Balaj, Leonora , Baldacchino, Shawn , Bauer, Natalie , Baxter, Amy A. , Bebawy, Mary , Beckham, Carla, Zavec, Apolonija Bedina, Benmoussa, Abderrahim , Berardi, Anna C. , Bergese, Paolo , Bielska, Ewa , Blenkiron, Cherie , Bobis‐Wozowicz, Sylwia , Boilard, Éric , Boireau, Wilfrid , Bongiovanni, Antonella , Borràs, Francesc E. , Bösch, Steffi , Boulanger, Chantal M. , Breakefield, Xandra O. , Breglio, Andrew , Brennan, Meadhbh Á. , Brigstock, David R. , Brisson, Alain , Broekman, Marike L. D. , Bromberg, Jacqueline , Bryl‐Górecka, Paulina , Burger, Dylan , Busatto, Sara , Buschmann, Dominik , Buzás, Edit I. , Byrd, James Brian , Carter, David R. F. , Caruso, Sarah , Chamley, Lawrence W. , Cheng, Lesley , Chin, Andrew R., Clayton, Aled , Clerici, Stefano Piatto , Cocks, Alex, Cocucci, Emanuele , Coffey, Robert J., Cordeiro‐da‐Silva, Anabela , Couch, Yvonne , Coumans, Frank A. W., Coyle, Beth , Crescitelli, Rossella , Criado, Miriã Ferreira, D’Souza‐Schorey, Crislyn , Chaudhuri, Amrita Datta , Candia, Paola de , Santana, Eliezer F De , Wever, Olivier De , Portillo, Hernando A. del , Demaret, Tanguy , Deville, Sarah , Devitt, Andrew , Dhondt, Bert , Vizio, Dolores Di , Rubio, Ana Paula Domínguez , Dourado, Maurício Rocha , Driedonks, Tom A. P. , Duarte, Filipe V. , Duncan, Heather M. , Eichenberger, Ramon M. , Ekström, Karin M. , Andaloussi, Samir EL , Élie-Caille, Céline , Erdbrügger, Uta , Fatima, Farah , Fish, Jason E. , Flores‐Bellver, Miguel , Försönits, András, Frelet‐Barrand, Annie , Fricke, Fabia , Fuhrmann, Gregor , Gámez‐Valero, Ana , Gardiner, Chris , Gärtner, Kathrin , Gaudin, Raphaël , Gho, Yong Song , Giebel, Bernd , Gilbert, Caroline , Gimona, Mario , Giusti, Ilaria , Goberdhan, Deborah C. I. , Görgens, André , Gorski, Sharon M. , Greening, David W. , Gross, Julia Christina , Gualerzi, Alice , Gupta, Gopal N. , Gustafson, Dakota , Handberg, Aase , Haraszti, Reka A. , Harrison, Paul , Hegyesi, Hargita , Hendrix, An , Hill, Andrew F. , Hochberg, Fred H. , Hoffmann, Karl F. , Holder, Beth , Holthöfer, Harry , Hosseinkhani, Baharak , Hu, Guoku , Huang, Yiyao , Huber, Veronica , Hunt, Stuart , Ibrahim, Ahmed , Ikezu, Tsuneya , Inal, Jameel M. , Işın, Mustafa , Ivanova, Alena , Jackson, Hannah K. , Jacobsen, Søren , Jay, Steven M. , Jayachandran, Muthuvel , Jenster, Guido , Jiang, Lanzhou , Johnson, Suzanne M. , Jones, Jennifer , Jong, Ambrose, Jovanović‐Talisman, Tijana , Jung, Stephanie , Kalluri, Raghu , Kano, Shin‐ichi , Kaur, Sukhbir , Kawamura, Yumi , Keller, Evan T. , Khamari, Delaram , Khomyakova, Elena , Kierulf, Peter, Kim, Kwang Pyo , Kislinger, Thomas , Klingeborn, Mikael , Klinke, David J. , Kornek, Miroslaw , Kosanović, Maja , Kovács, Árpád Ferenc , Krämer‐Albers, Eva‐Maria , Krause, Mirja, Kurochkin, Igor V. , Kuypers, Sören , Laitinen, Saara , Langevin, Scott M. , Languino, Lucia R. , Lässer, Cecilia , Laurent, Louise C. , Lázaro‐Ibáñez, Elisa , Lay, Soazig Le , Lee, Myung‐Shin , Lee, Yi , Lemos, Débora S., Lenassi, Metka , Leszczynska, Aleksandra , Li, Isaac T. S. , Liao, Ke , Libregts, Sten F.W.M. , Ligeti, Erzsébet , Lim, Rebecca , Lim, Sai Kiang , Linē, Aija , Linnemannstöns, Karen, Llorente, Alicia , Lorenowicz, Magdalena J. , Lőrincz, Ákos M. , Lovett, Jason , Lowry, Michelle C., Loyer, Xavier , Lu, Quan , Łukomska, Barbara , Lunavat, Taral R. , Marcilla, Antonio , Mariani, Jacopo , Mariscal, Javier , Martens‐Uzunova, Elena S. , Martín‐Jaular, Lorena , Martínez, Maria Carmen , Martins, Vilma R. , Mathieu, Mathilde , Mathivanan, Suresh , Maugeri, Marco , McGinnis, Lynda K. , McVey, Mark J. , Meckes, David G. , Meehan, Katie , Jørgensen, Maléne Møller , Morhayim, Jess , Muraca, Maurizio , Musante, Luca , Mussack, Veronika , Muth, Dillon C. , Myburgh, Kathryn H. , Najrana, Tanbir , Nawaz, Muhammad , Nazarenko, Irina , Nejsum, Peter , Néri, Christian , Nolan, John P. , Hoen, Esther Nm Nolte-'t, Hooten, Nicole Noren , O’Grady, Tina , Ochiya, Takahiro , Olivier, Martin , Ortíz, Alberto , Ortiz, Luis A. , Osteikoetxea, Xabier , Østergaard, Ole , Ostrowski, Matías , Pegtel, D. Michiel , Peinado, Héctor , Perut, Francesca , Pfaffl, Michael W. , Phinney, Donald G. , Pieters, Bartijn C. H. , Pink, Ryan , Pisetsky, David S. , Strandmann, Elke Pogge von , Polakovičová, Iva , Poon, Ivan K. H. , Powell, Bonita H. , Prada, Ilaria , Pulliam, Lynn , Quesenberry, Peter J. , Radeghieri, Annalisa , Raffaı̈, Robert L. , Rak, Janusz , Ramirez, Marcel I. , Raposo, Graça , Rayyan, Morsi , Ricklefs, Franz , Roberts, David D. , Rodrigues, Sílvia C. , Rohde, Eva , Rome, Sophie , Rouschop, Kasper M.A. , Rughetti, Aurelia , Russell, Ashley E. , Sahoo, Susmita , Salas‐Huenuleo, Edison , Sánchez, Catherine , Saugstad, Julie A. , Saul, Meike J. , Schneider, Raphaël , Schøyen, Tine Hiorth , Scott, Aaron , Shahaj, Eriomina , Sharma, Shivani , Shatnyeva, Olga , Shekari, Faezeh , Shelke, Ganesh Vilas , Shiba, Kiyotaka , Siljander, Pia , Silva, Andreia , Skowronek, Agata, Snyder, Orman L., Sódar, Barbara W., Soekmadji, Carolina , Stahl, Philip D., Stoorvogel, Willem , Stott, Shannon L. , Strasser, Erwin , Tahara, Hidetoshi , Tewari, Muneesh , Timms, Kate , Tiwari, Swasti , Tixeira, Rochelle , Toh, Wei Seong , Tomasini, Richard , Tosar, Juan Pablo , Toxavidis, Vasilis, Urbanelli, Lorena , Vader, Pieter , Balkom, Bas WM van, Grein, Susanne G van der, Deun, Jan Van , Herwijnen, Martijn J. C. van , Keuren‐Jensen, Kendall Van , Niel, Guillaume van , Royen, Martin E. van , Wijnen, André J. van , Vasconcelos, M. Helena , Vechetti, Ivan J. , Vella, Laura J. , Velot, Émilie , Verweij, Frederik J. , Vestad, Beate , Viñas, Jose L. , Visnovitz, Tamás , Vukman, Krisztina V , Wahlgren, Jessica, Watson, Dionysios C. , Wauben, Marca H. M. , Weaver, Alissa M. , Webber, Jason , Weber, Viktoria , Wehman, Ann M. , Welsh, Joshua A , Wheelock, Åsa M. , Wiener, Zoltán , Witte, Leonie , Wolfram, Joy , Xagorari, Angeliki , Xander, Patrícia , Xu, Jing , Yan, Xiaomei , Yin, Hang , Yuana, Yuana, Zappulli, Valentina , Zárubová, Jana , Žėkas, Vytautas , Zhang, Jianye , Zhao, Zezhou , Zickler, Antje M. , Zimmermann, Pascale , Zivkovic, Angela M. , Zocco, Davide, Zuba‐Surma, Ewa , Malhi, Harmeet , Peinado, Héctor , van Wijnen, Andre J , Bergese, Paolo , Kim, Kwang Pyo , Ikezu, Tsuneya , Wolfram, Joy , Lenassi, Metka , Gualerzi, Alice , Nazarenko, Irina , Pink, Ryan , Siljander, Pia R-M , Welsh, Joshua A , Witwer, Kenneth W , Hill, Andrew F , Coyle, Beth , Saugstad, Julie A , Buch, Shilpa J. , Buck, Amy H. , Bussolati, Benedetta , Camussi, Giovanni , Chang, Yu‐Ting , Chen, Chihchen , Chen, Daiwen , Criado, Miriã Ferreira , Das, Saumya , Dieterich, Lothar C. , Dolo, Vincenza , Dominici, Massimo , Falcón‐Pérez, Juan Manuel , Gabrielsson, Susanne , Khvorova, Anastasia , Krasemann, Susanne , Kusuma, Gina Diamanta , Lannigan, Joanne , Laurent, Louise C , Lavieu, Grégory , Lombard, Catherine Anne , Lötvall, Jan , Maas, Sybren L. N. , Mertens, Inge , Minciacchi, Valentina R. , Möller, Andreas , Morales‐Kastresana, Aizea , Mullier, François , Neri, Tommaso , Nieuwland, Rienk , Nimrichter, Leonardo , O’Driscoll, Lorraine , O’Loghlen, Ana , Park, Jaesung , Raimondo, Stefania , Regev‐Rudzki, Neta , Robbins, Paul D. , Saá, Paula , Schiffelers, Raymond Michel , Shetty, Ashok Kumar , Soares, Rodrigo Pedro , Sotillo, Javier , Swift, Simon , Tkach, Mercedes , Torrecilhas, Ana Cláudia , Balkom, Bas W. M. van , Grein, Susanne G. van der, Veit, Tiago Degani , Weiss, Daniel J. , Wendt, Sebastian, Yáñez‐Mó, María , Zheng, Lei , Zheutlin, Alexander R. , Borràs, Francesc E , Martens-Uzunova, Elena S , Buzas, Edit I , Giebel, Bernd , Jones, Jennifer C , Ortiz, Alberto , Greening, David W

Mayo Clinic

Journal of Extracellular Vesicles | November 24, 2018 | Volume: 7 | Issue: 1 | Pages: No page available

10.1080/20013078.2018.1535750 | PMID 30637094 Get It

ABSTRACT The last decade has seen a sharp increase in the number of scientific publications describing physiological and pathological functions of extracellular vesicles (EVs), a collective term covering various subtypes of cell‐released, membranous structures, called exosomes, microvesicles, microparticles, ectosomes, oncosomes, apoptotic bodies, and many other names. However, specific issues arise when working with these entities, whose size and amount often make them difficult to obtain as relatively pure preparations, and to characterize properly. The International Society for Extracellular Vesicles (ISEV) proposed Minimal Information for Studies of Extracellular Vesicles (“MISEV”) guidelines for the field in 2014. We now update these “MISEV2014” guidelines based on evolution of the collective knowledge in the last four years. An important point to consider is that ascribing a specific function to EVs in general, or to subtypes of EVs, requires reporting of specific information beyond mere description of function in a crude, potentially contaminated, and heterogeneous preparation. For example, claims that exosomes are endowed with exquisite and specific activities remain difficult to support experimentally, given our still limited knowledge of their specific molecular machineries of biogenesis and release, as compared with other biophysically similar EVs. The MISEV2018 guidelines include tables and outlines of suggested protocols and steps to follow to document specific EV‐associated functional activities. Finally, a checklist is provided with summaries of key points.